Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options	ANNALS OF HEMATOLOGY	2024
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries	BRITISH JOURNAL OF HAEMATOLOGY	2024
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia	CANCERS	2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2024
Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study	EUROPEAN JOURNAL OF HAEMATOLOGY	2024
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real-world case series	BRITISH JOURNAL OF HAEMATOLOGY	2024
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study	ANNALS OF HEMATOLOGY	2024
SUSTRENIM TRIAL: SUSTAINED DEEP MOLECULAR RESPONSE AND TFR RATE IN THE LONG-TERM FOLLOWUP	HEMASPHERE	2024
OPTIMAL DURATION OF CPX-351 TREATMENT AND BEST TIMING FOR CONSOLIDATION WITH ALLOGENEIC STEM CELL TRANSPLANTATION: EVIDENCE FROM A LARGE REAL-WORLD ITALIAN STUDY	HEMASPHERE	2024
PROGNOSTIC RELEVANCE OF TP53 MUTATIONS WITH OR WITHOUT CONCOMITANT COMPLEX KARYOTYPE IN PATIENTS TREATED WITH CPX-351: EVIDENCE FROM A LARGE REAL-WORLD ITALIAN STUDY	HEMASPHERE	2024
QUALITY OF LIFE BENEFITS OF ATO VS CHEMOTHERAPY IN PATIENTS WITH APL ARE SUSTAINED OVER TIME: RESULTS FROM THE GIMEMA APL0406	HEMASPHERE	2024
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 657 ITALIAN PATIENTS	HEMASPHERE	2024
DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. ELIGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI: THE LABNET CML NATIONAL NETWORK	HEMASPHERE	2024
PROPENSITY SCORE MATCHING ANALYSIS COMPARING ASCIMINIB VERSUS PONATINIB FOR ITS TREATMENT OUTOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS	HEMASPHERE	2024
CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB	HEMASPHERE	2024
REVISED “IRR6” MODEL IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB	HEMASPHERE	2024
RUXOLITINIB STARTING DOSE REDUCTION AFFECT OVERALL SURVIVAL IN MYELOFIBROSIS: AIFA MONITORING REGISTRIES ANALYSIS	HEMASPHERE	2024
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION	HEMASPHERE	2024
BASELINE QUALITY OF LIFE DATA MAY PREDICT ACHIEVEMENT OF EMR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TKIS: RESULTS FROM THE GIMEMA-SUSTRENIM TRIAL	HEMASPHERE	2024
HYPEREOSINOPHILIC DISORDERS: PRELIMINARY REAL-WORLD ANALYSIS BY PH-NEGATIVE MPN LATIAL GROUP	HEMASPHERE	2024